<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680910</url>
  </required_header>
  <id_info>
    <org_study_id>202008037</org_study_id>
    <nct_id>NCT04680910</nct_id>
  </id_info>
  <brief_title>Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) - Phase I</brief_title>
  <official_title>Precision Targeting of Propofol-induced Electroencephalographic Slow Waves: a Novel Phase I Paradigm for Treatment-resistant Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our overall hypothesis is that sleep slow-wave potentiation by propofol is a therapeutic&#xD;
      pathway for alleviating treatment-resistant depression (TRD).&#xD;
&#xD;
      This investigation aims to establish:&#xD;
&#xD;
      Aim 1: Establish the safety and feasibility of multiple propofol infusions targeting of&#xD;
      electroencephalographic (EEG) slow-wave activity (SWA) without burst suppression in geriatric&#xD;
      patients with treatment-resistant depression (TRD) patients.&#xD;
&#xD;
      Prospective, mechanistic, open-label for safety/feasibility pilot study (target enrollment =&#xD;
      15)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot Study for safety and feasibility</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Slow Wave Activity</measure>
    <time_frame>Up to 4 weeks following consent</time_frame>
    <description>SWA during sedation will be calculated as the total power in the 1-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 1-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I: Propofol infusion - moderate dose</intervention_name>
    <description>Targeted propofol infusion at a moderate range dose in TRD patients will induce SWA during sedation and augment sleep SWA. Dosage of propofol is determined based upon EEG markers.</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electroencephalographic (EEG)</intervention_name>
    <description>EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Slow-Wave Activity</intervention_name>
    <description>Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 1-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 1-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60 or older&#xD;
&#xD;
          -  history of treatment-resistant depression (failure of two oral antidepressant classes)&#xD;
&#xD;
          -  baseline deficiency in N3 sleep&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic coronary artery disease&#xD;
&#xD;
          -  congestive heart failure or cardiomyopathy&#xD;
&#xD;
          -  history of TIA or cognitive symptoms in the past year&#xD;
&#xD;
          -  allergy to propofol&#xD;
&#xD;
          -  pulse&lt;60 bpm at baseline&#xD;
&#xD;
          -  concurrent/recent (within 6 weeks) neuromodulatory stimulation for depression&#xD;
             (ECT/TMS)&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Palanca, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Nguyen</last_name>
    <phone>314-273-2454</phone>
    <email>nguyen.t@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine/Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Nguyen</last_name>
      <phone>314-273-2454</phone>
      <email>nguyen.t@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ben Palanca, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy MJ, Peterson MJ. Sleep Disturbances in Depression. Sleep Med Clin. 2015 Mar;10(1):17-23. doi: 10.1016/j.jsmc.2014.11.009. Epub 2014 Dec 12. Review.</citation>
    <PMID>26055669</PMID>
  </reference>
  <reference>
    <citation>Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11. doi: 10.1017/S1461145712000545. Epub 2012 Jun 7.</citation>
    <PMID>22676966</PMID>
  </reference>
  <reference>
    <citation>Doghramji K, Jangro WC. Adverse Effects of Psychotropic Medications on Sleep. Psychiatr Clin North Am. 2016 Sep;39(3):487-502. doi: 10.1016/j.psc.2016.04.009. Epub 2016 Jun 24. Review.</citation>
    <PMID>27514301</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ben Palanca</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

